Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Anhui Kedgene Biotechnology

Main focus: Next generation T cell-based therapies

Company stage: Clinical

Diseases: Solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Anhui, China

Website: https://www.ankebio.com/english/index.php

Anhui Kedgene Biotechnology develops next generation T cell-based therapies for solid tumour treatment. The company uses CRISPR to knock out PD-1 from its T cell products, in order to optimise efficacy and safety.

Anhui Kedgene Biotechnology Co.,Ltd

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

Harmonising the Community of Genome Editing with...

Nov. 28, 2022

Samantha Maragh from the US National Institute of Standards and Technology (NIST) discusses the significance of the recent publication of a set of...

CMN Weekly (25 November 2022) - Your Weekly CRISPR...

Nov. 25, 2022

Some of the best links we picked up around the internet

Eligo Bioscience Announces Broadest Prokaryotic...

Press Release Service

Nov. 22, 2022

Eligo Bioscience announced today the issuance by the US Patent and Trademark Office of a landmark CRISPR patent that broadly covers any therapeutic...

CMN Weekly (18 November 2022) - Your Weekly CRISPR...

Nov. 18, 2022

Some of the best links we picked up around the internet

Clinical Update: Promising Results From...

Nov. 16, 2022

Last week, PACT Pharma shared results from the first clinical trial using CRISPR to direct patients’ immune cells to treat solid tumours. The...

Webinar

Development of CRISPR/Cas9-based Therapies against...

Nov. 14, 2022

Read more about the webinar - Development of CRISPR/Cas9-based Therapies against Alzheimer's Disease